CN103705761B - Traditional Chinese medicine for treating cerebral hemorrhage diseases - Google Patents
Traditional Chinese medicine for treating cerebral hemorrhage diseases Download PDFInfo
- Publication number
- CN103705761B CN103705761B CN201410014178.1A CN201410014178A CN103705761B CN 103705761 B CN103705761 B CN 103705761B CN 201410014178 A CN201410014178 A CN 201410014178A CN 103705761 B CN103705761 B CN 103705761B
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- cerebral hemorrhage
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 65
- 206010008111 Cerebral haemorrhage Diseases 0.000 title claims abstract description 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 28
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 51
- 239000002994 raw material Substances 0.000 claims abstract description 37
- 239000000203 mixture Substances 0.000 claims abstract description 24
- 239000000654 additive Substances 0.000 claims abstract description 20
- 230000000996 additive effect Effects 0.000 claims abstract description 19
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 17
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000000811 xylitol Substances 0.000 claims abstract description 17
- 235000010447 xylitol Nutrition 0.000 claims abstract description 17
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 17
- 229960002675 xylitol Drugs 0.000 claims abstract description 17
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 9
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 9
- 241000305491 Gastrodia elata Species 0.000 claims abstract description 9
- 241000361919 Metaphire sieboldi Species 0.000 claims abstract description 9
- 241000316658 Sauromatum giganteum Species 0.000 claims abstract description 9
- 241000157352 Uncaria Species 0.000 claims abstract description 9
- 241000185686 Apocynum venetum Species 0.000 claims abstract description 8
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims abstract description 8
- 241000304195 Salvia miltiorrhiza Species 0.000 claims abstract 3
- 239000000463 material Substances 0.000 claims description 28
- 238000001035 drying Methods 0.000 claims description 22
- 238000003756 stirring Methods 0.000 claims description 13
- 241000218236 Cannabis Species 0.000 claims description 8
- 241000239226 Scorpiones Species 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 6
- 238000007873 sieving Methods 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 5
- 241000722949 Apocynum Species 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 23
- 231100000331 toxic Toxicity 0.000 abstract description 10
- 230000002588 toxic effect Effects 0.000 abstract description 10
- 206010013663 drug dependence Diseases 0.000 abstract description 6
- 208000011117 substance-related disease Diseases 0.000 abstract description 6
- 241000522620 Scorpio Species 0.000 abstract 1
- 240000004308 marijuana Species 0.000 abstract 1
- 239000009490 scorpio Substances 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 206010020772 Hypertension Diseases 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 210000005036 nerve Anatomy 0.000 description 5
- 244000132619 red sage Species 0.000 description 5
- 206010008190 Cerebrovascular accident Diseases 0.000 description 4
- 206010019468 Hemiplegia Diseases 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 230000001914 calming effect Effects 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 102000003946 Prolactin Human genes 0.000 description 3
- 108010057464 Prolactin Proteins 0.000 description 3
- 208000005392 Spasm Diseases 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 235000008216 herbs Nutrition 0.000 description 3
- 238000007917 intracranial administration Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 229940118019 malondialdehyde Drugs 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 229940097325 prolactin Drugs 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 208000000044 Amnesia Diseases 0.000 description 2
- 208000031091 Amnestic disease Diseases 0.000 description 2
- 206010053942 Cerebral haematoma Diseases 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 206010011878 Deafness Diseases 0.000 description 2
- 241000545744 Hirudinea Species 0.000 description 2
- 244000241838 Lycium barbarum Species 0.000 description 2
- 235000015459 Lycium barbarum Nutrition 0.000 description 2
- 235000015468 Lycium chinense Nutrition 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 241001243666 Photinia serratifolia Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000006986 amnesia Effects 0.000 description 2
- 201000007201 aphasia Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 231100000895 deafness Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 208000016354 hearing loss disease Diseases 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 208000034783 hypoesthesia Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 229930192334 Auxin Natural products 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 208000022540 Consciousness disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101001009581 Molluscum contagiosum virus subtype 1 Glutathione peroxidase Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010043269 Tension headache Diseases 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 208000009443 Vascular Malformations Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 239000002363 auxin Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 210000001736 capillary Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002892 effect on hypertension Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000024121 nodulation Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 235000005412 red sage Nutrition 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- -1 sucrose fatty acid ester Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000009602 toxicology test Methods 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 1
- 235000019801 trisodium phosphate Nutrition 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine for treating cerebral hemorrhage diseases. The traditional Chinese medicine consists of the following raw materials in parts by weight: 30-35 parts of scorpio, 15-25 parts of uncaria, 30-35 parts of earthworm, 25-30 parts of typhonium giganteum, 5-10 parts of cassia twig, 25-30 parts of salvia miltiorrhiza, 2-4 parts of bud apocynum venetum, 30-35 parts of gastrodia elata, 5-6 parts of fructus cannabis, 30-35 parts of rhizoma acori graminei and 5-8 parts of additive, wherein the additive is a mixture of xylitol and citric acid. The traditional Chinese medicine is convenient to take, short in course of treatment and fast in effectiveness and does not have a toxic or side effect, and drug dependence is avoided.
Description
Technical Field
The invention belongs to the field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine for treating cerebral hemorrhage diseases.
Background
Cerebral hemorrhage, commonly known as cerebral hemorrhage, belongs to one of cerebral apoplexy and is a common serious cerebral complication of middle-aged and old-aged hypertension patients. Cerebral hemorrhage refers to hemorrhage caused by rupture of blood vessels in non-traumatic brain parenchyma, the most common causes are hypertension, cerebral arteriosclerosis, intracranial vascular malformation and the like, and the cerebral hemorrhage is induced by factors such as strength, emotional agitation and the like, so the cerebral hemorrhage usually occurs suddenly in activity, and is clinically very rapid and mainly manifested as damage of nervous systems such as consciousness disorder, limb hemiplegia, aphasia and the like. It has sudden onset, serious illness and high death rate, and is one of the lethal diseases of the middle-aged and the elderly at present.
At present, comprehensive treatment is generally adopted for treatment, including western medicine comprehensive treatment, traditional Chinese medicine comprehensive treatment and traditional Chinese and western medicine comprehensive treatment, wherein the traditional Chinese and western medicine comprehensive treatment has a good effect on mortality and disability rate, but an effective medicine is still lacked. Moreover, the recovery process of the cerebral hemorrhage disease is long, long-term medication is needed, and the drug dependence is easy to form, so that a drug which is convenient to take, short in treatment course, quick in effect, free of toxic and side effects and free of drug dependence is urgently needed.
Disclosure of Invention
In order to solve the problems, the invention provides the traditional Chinese medicine for treating the cerebral hemorrhage disease, which can effectively treat hypertension and cerebral hemorrhage sequelae, and has the advantages of convenient administration, short treatment course, quick response, no toxic or side effect and no drug dependence.
The technical scheme adopted by the invention for solving the technical problems is a traditional Chinese medicine for treating cerebral hemorrhage diseases, which is prepared from the following raw materials in parts by weight: 30-35 parts of scorpion, 15-25 parts of uncaria, 30-35 parts of earthworm, 25-30 parts of typhonium giganteum, 5-10 parts of cassia twig, 25-30 parts of salvia miltiorrhiza, 2-4 parts of apocynum venetum, 30-35 parts of gastrodia elata, 5-6 parts of fructus cannabis, 30-35 parts of rhizoma acori graminei and 5-8 parts of additive, wherein the additive is a mixture of xylitol and citric acid;
the traditional Chinese medicine is prepared by the following steps:
1) weighing clean raw materials according to the parts by weight except a mixture of xylitol and citric acid, uniformly mixing, drying at 65-75 ℃ for 15-20 minutes, and uniformly stirring while drying; then, the raw materials are put into a crusher to be crushed into coarse materials, and the coarse materials are sieved by a sieve of 50-80 meshes;
2) uniformly mixing the raw materials crushed in the step 1), drying at 70-80 ℃ for 10-15 minutes, and uniformly stirring while drying; then putting the mixture into a fine crusher to be crushed into fine materials, sieving the fine materials by a sieve of 150-180 meshes, and uniformly mixing the fine materials;
3) then the admixture in parts by weight is mixed, and then the mixture is stirred evenly, bagged, packaged and sterilized to obtain the powder type traditional Chinese medicine for treating cerebral hemorrhage diseases.
Preferably, the traditional Chinese medicine is prepared from the following raw materials in parts by weight: 32 parts of scorpion, 20 parts of uncaria, 32 parts of earthworm, 28 parts of typhonium giganteum, 8 parts of cassia twig, 28 parts of salvia miltiorrhiza, 3 parts of dogbane, 32 parts of gastrodia elata, 5.5 parts of fructus cannabis and 32 parts of rhizoma acori graminei.
In any of the above embodiments, preferably, 1 part by weight of the raw material is 10 g.
In any of the above embodiments, preferably, the weight ratio of xylitol to citric acid in the admixture is 1: 0.5.
In any of the above embodiments, the bag preferably has a weight of 20 g.
Wherein,
whole worm: liver calming and wind stopping herbs and wind dispelling herbs; pungent and mild; it enters liver meridian. Extinguish wind and relieve spasm, counteract toxic pathogen and dissipate nodulation, unblock collaterals and alleviate pain, and treat crooked middle-jiao wind gap and hemiplegia.
Uncaria: herbs for calming liver and stopping wind enter liver meridian and heart meridian; clearing heat and calming the liver; calming endogenous wind and relieving spasm; it can be used for treating vertigo due to liver-yang, liver fire, headache, and hypertension.
Earthworm: cold in nature and salty in taste. Clearing heat, arresting convulsion, dredging collaterals, relieving asthma, and promoting urination; can be used for treating cerebral thrombosis, cerebral infarction, coronary heart disease, apoplexy, articulation paralysis, limb numbness, hemiplegia, and hypertension.
Typhonium giganteum: dispelling pathogenic wind and phlegm, dispelling cold and dampness, relieving spasm, and treating headache, facial distortion, hemiplegia, tetanus, traumatic injury, fatigue, numbness of limbs, and aphasia due to apoplexy.
Cassia twig: entering liver, kidney and spleen, is a commonly used interior-warming medicine for treating interior cold, and has the efficacies of tonifying primordial yang, promoting blood circulation and warming spleen and stomach.
Red sage root: it enters heart and liver meridians, and has effects of dispelling blood stasis, relieving pain, promoting blood circulation, regulating menstruation, reducing blood fat, reducing weight, clearing heart fire, and relieving restlessness. Can be used for treating cardiovascular and cerebrovascular diseases, obesity, and hyperlipidemia.
And (3) young bud apocynum venetum: the medicine effect value of the traditional Chinese medicine is 72 times of that of the same apocynum venetum, and the traditional Chinese medicine can reduce blood pressure, blood fat and increase coronary flow, has better curative effect on hypertension and hyperlipidemia, and is non-toxic, free of side effect and free of dependence.
Gastrodia elata: relieving pain, tranquilizing mind, relieving convulsion, lowering blood pressure, improving eyesight, and improving intelligence.
Fructus cannabis: the medicine has the effects of moistening intestines, relaxing bowels, moistening dryness and killing insects, and can prevent constipation caused by postoperative bed rest.
Grassleaf sweelflag rhizome: resolve dampness, stimulate appetite, induce resuscitation, eliminate phlegm, refresh mind and promote intelligence. Can be used for treating epigastric fullness, inappetence, dysentery, coma, epilepsy, amnesia, and deafness. Regulating qi, promoting blood circulation, dispelling pathogenic wind, and removing dampness. It can be used for treating epilepsy, phlegm syncope, fever, coma, amnesia, qi block, deafness, vexation, gastralgia, abdominal pain, arthralgia due to wind-cold-dampness, superficial infection, toxic swelling, and traumatic injury.
Xylitol and citric acid: additives and sweetening agents to enhance normal metabolism in vivo.
The invention has the beneficial effects that:
1. the traditional Chinese medicine for treating the cerebral hemorrhage disease is convenient to take, short in treatment course, quick in effect, free of toxic and side effects and free of drug dependence.
2. The traditional Chinese medicine has the effects of activating blood stasis, stopping bleeding, dredging lung and purging heat, reducing intracerebral hematoma, reducing intracranial pressure, relieving encephaledema and promoting recovery of nerve function.
3. The raw materials of the traditional Chinese medicine can fully utilize the resources of artificial planting, the sufficiency of the raw material resources is guaranteed, the efficiency is high, and the economic benefit and the social benefit are obvious.
The traditional Chinese medicine raw materials are obtained through verification, recording and testing for years, although the efficacies of the raw materials are different, the selection of each traditional Chinese medicine is not random, the proportion of the raw materials obtained through the testing for years is not simple and superposed, because various traditional Chinese medicine raw materials possibly have various action relationships such as growing, reinforcing, mutual incompatibility and killing, and the like, the raw materials are correspondingly selected according to the principle, and the optimal proportion among the raw materials is determined, so the application has remarkable significance.
The safety toxicology test shows that the traditional Chinese medicine of the invention: LD50 is 8500mg/kg, and the safety toxicology evaluation is nontoxic level and has no toxic and side effects.
Acute toxicity test
The experimental samples are prepared into suspension, and the suspension is administrated to mice by intragastric administration at the dose which is 400 times of the daily clinical dose, and no toxic reaction of animals is found during the observation period. None of the animals died when observed for 14 days of dosing; after the animal is sacrificed and dissected, the visceral organs of the animal are observed without obvious abnormality. Experiments show that half of lethal dose of the invention can not be detected by gastric lavage administration, and the tolerance of animal experiments is 305 times of the maximum dose of clinical adults every day.
Long term toxicity test in animals
The samples are provided for rats for long-term administration for 6 months in a clinical daily dose of 5 times, 15 times and 75 times, and common activities, mental states, hairs, excrement and the like of the two doses of the raticide have no obvious abnormality; the peripheral hemogram including erythrocyte, leucocyte and classification, hemoglobin and hematocrit fluctuate within normal range before and after administration; no obvious influence on liver and kidney function indexes is seen; at the end of the test, the contents of total protein, albumin and alkaline phosphatase in the animal serum are not obviously different from those of a control group; no abnormality is found in electrocardiographic examination; the gross inspection of each main organ does not show obvious pathological morphological changes such as swelling, congestion, necrosis and the like; the weight coefficients of organs such as heart, liver, spleen, lung, kidney, thymus, adrenal gland and the like have no significant difference compared with the control group; no abnormality is found in the pathological histological examination. The above results show that the invention is relatively safe and has no obvious toxic and side effects within the dosage range of the reagent.
Main pharmacodynamic experiments:
the samples are administrated by two dosage groups of which the clinical daily dosage is 38 times and 10 times, and the cerebral hemorrhage model of a rat is induced by injecting collagenase VII to S collagenase of about 0.5 u/mu L by taking the Naoxuekang as a control group and is sutured. Animals were scored immediately upon awakening. After 7 and 14 days of administration, nerve dysfunction, water content of brain tissue, activity of superoxide dismutase (SOD), glutathione peroxidase (GSHPx) and content of Malondialdehyde (MDA) in the brain tissue, concentration of triiodothyronine (T3), thyroxine (T4), auxin (GH), Prolactin (PRL) and Cortisol (CS) in blood, and observation of electron microscope and light microscope observation of HE staining, VG staining, silver staining and GFAP immunohistochemical staining are observed. As a result: the traditional Chinese medicine treatment group accelerates the recovery of animal nerve dysfunction, accelerates the abnormal recovery of blood T3, T4, GH and PRL, and reduces the abnormal recovery of SOD and MDA in brain tissues; histopathology suggests that cerebral edema is reduced, neuronal ischemic necrosis is reduced, the number of new capillaries, phagocytes and astrocytes is increased, and the production of glial fibers is increased; the effect of the large dose treatment group is most obvious.
Detailed Description
The present invention will be further described with reference to the following embodiments.
Example 1
The traditional Chinese medicine for treating cerebral hemorrhage diseases is prepared from the following raw materials in parts by weight: 30g of scorpion, 25g of uncaria, 30g of earthworm, 30g of typhonium giganteum, 5g of cassia twig, 30g of salvia miltiorrhiza, 2g of apocynum venetum, 35g of gastrodia elata, 5g of fructus cannabis, 35g of rhizoma acori graminei and 5g of additive, wherein the additive is a mixture of xylitol and citric acid;
the traditional Chinese medicine is prepared by the following steps:
1) weighing clean raw materials according to the parts by weight except a mixture of xylitol and citric acid, uniformly mixing, drying at 75 ℃ for 15 minutes, and uniformly stirring while drying; then, the raw materials are put into a crusher to be crushed into coarse materials, and the coarse materials are sieved by a 80-mesh sieve;
2) uniformly mixing the raw materials crushed in the step 1), drying for 15 minutes at 70 ℃, and uniformly stirring while drying; then putting the mixture into a fine pulverizer to pulverize the mixture into fine materials, sieving the fine materials with a 150-mesh sieve, and uniformly mixing the fine materials;
3) then 5g of admixture is added, and then the mixture is stirred evenly, bagged, packaged and sterilized to obtain the powder type traditional Chinese medicine for treating cerebral hemorrhage diseases.
Wherein the weight ratio of the xylitol to the citric acid in the admixture is 1:0.5, and the weight of the bagged additive is 20 g.
Example 2
The traditional Chinese medicine for treating cerebral hemorrhage diseases is prepared from the following raw materials in parts by weight: 35g of scorpion, 15g of uncaria, 35g of earthworm, 25g of typhonium giganteum, 10g of cassia twig, 25g of salvia miltiorrhiza, 4g of apocynum venetum, 30g of gastrodia elata, 6g of fructus cannabis, 30g of rhizoma acori graminei and 8g of additive, wherein the additive is a mixture of xylitol and citric acid;
the traditional Chinese medicine is prepared by the following steps:
1) weighing clean raw materials according to the parts by weight except the mixture of xylitol and citric acid, uniformly mixing, drying at 65 ℃ for 20 minutes, and uniformly stirring while drying; then, the raw materials are put into a crusher to be crushed into coarse materials, and the coarse materials are sieved by a 50-mesh sieve;
2) uniformly mixing the raw materials crushed in the step 1), drying for 10 minutes at 80 ℃, and uniformly stirring while drying; then putting the mixture into a fine pulverizer to pulverize the mixture into fine materials, sieving the fine materials with a 180-mesh sieve, and uniformly mixing the fine materials;
3) then 8g of admixture is added, and then the mixture is stirred evenly, bagged, packaged and sterilized to obtain the powder type traditional Chinese medicine for treating cerebral hemorrhage diseases.
Wherein the weight ratio of the xylitol to the citric acid in the admixture is 1:0.5, and the weight of the bagged additive is 20 g.
Example 3
The traditional Chinese medicine for treating cerebral hemorrhage diseases is prepared from the following raw materials in parts by weight: 32g of scorpion, 20g of uncaria, 32g of earthworm, 28g of typhonium giganteum, 8g of cassia twig, 28g of salvia miltiorrhiza, 3g of apocynum venetum, 32g of gastrodia elata, 5.5g of fructus cannabis, 32g of rhizoma acori graminei and 6g of additive, wherein the additive is a mixture of xylitol and citric acid;
the traditional Chinese medicine is prepared by the following steps:
1) weighing clean raw materials according to the parts by weight except the mixture of xylitol and citric acid, uniformly mixing, drying at 670 ℃ for 18 minutes, and uniformly stirring while drying; then, the raw materials are put into a crusher to be crushed into coarse materials, and the coarse materials are sieved by a 60-mesh sieve;
2) uniformly mixing the raw materials crushed in the step 1), drying at 75 ℃ for 12 minutes, and uniformly stirring while drying; then putting the mixture into a fine crusher to be crushed into fine materials, sieving the fine materials with a 160-mesh sieve, and uniformly mixing the fine materials;
3) then 6g of admixture is added, and then the mixture is stirred evenly, bagged, packaged and sterilized to obtain the powder type traditional Chinese medicine for treating cerebral hemorrhage diseases.
Wherein the weight ratio of the xylitol to the citric acid in the admixture is 1:0.5, and the weight of the bagged additive is 20 g.
Clinical practice
Case 1: wu Chi, female, 65 years old, had cerebral hemorrhage in 2011, and was completely unable to take care of oneself when discharged 42 days after hospitalization. After the traditional Chinese medicine is taken, the patient can walk by hands after 20 days, can take care of himself after 2 months, continues to take the medicine, and does not relapse until now.
Case 2: yan when men and 42 years old get hypertension and hyperlipidemia in 2012, cerebral hemorrhage is caused by frequent western medicine taking. The disease condition is not improved after hospitalization for two weeks. After taking the traditional Chinese medicine, the illness state is relieved after one week, the life can be managed by oneself after two weeks, and the life can be managed by oneself after one month. After the medicine is continuously taken for 2 months, the disease is cured, and the disease does not relapse.
In addition, the traditional Chinese medicine is used for special clinical research.
Object: 350 patients with cerebral hemorrhage, wherein the age is 35-75 years, 203 patients are male, and 147 patients are female.
Diagnostic criteria: all the patients are diagnosed by CT, which accords with the diagnosis standard of 'cerebral hemorrhage' in western medicine and the standard of apoplexy in traditional Chinese medicine, the onset time is within 7 days, and serious heart, lung, liver, kidney or various blood diseases, mental diseases and the like are combined.
The method comprises the following steps: the bagged medicament in the embodiment is taken by patients with cerebral hemorrhage sequelae once a day in the morning and at night according to the dose of 200 mL/time, and is observed at follow-up visit for 6 months. Wherein the life can be self-care and can be independently walked is cured; muscle strength recovery to grade 4 is effective; the remainder are invalid.
As a result: the cure rate of the treatment is 45%, and 157 cases of cure are 70 cases for male and 87 cases for female; the total effective rate is 91.5%, and 320 cases are cured, wherein 150 cases are male and 170 cases are female. The traditional Chinese medicine has remarkable effects in recovering nerve function, improving life quality and absorbing hematoma. The diagnosis of the disease condition is informed of the diagnosis of the doctor issued by the regular hospital.
In order to enhance the effect of the traditional Chinese medicine, 15-20 parts by weight of raw leech, 10-15 parts by weight of photinia serrulata and 5-8 parts by weight of wolfberry fruit can be added into the raw materials; and 2-5 parts by weight of a second additive can be added, wherein the second additive is composed of sucrose fatty acid ester, mannitol crystals, natural menthol, trisodium phosphate, saccharin sodium and stevioside, and the weight ratio of the components is 1: 0.5: 2: 0.5. Drying raw leeches, photinia serrulata and barbary wolfberry fruits for 15-20 minutes at 65-75 ℃, uniformly stirring while drying, then crushing into fine materials by using a crusher, sieving by using a 300-mesh sieve, directly mixing the fine materials sieved by the 300-mesh sieve into the fine materials of the traditional Chinese medicine raw materials, stirring the mixture with the additive and the second additive in parts by weight, and then uniformly stirring, bagging, packaging and sterilizing to obtain the powder type traditional Chinese medicine for treating the cerebral hemorrhage diseases.
The traditional Chinese medicine for treating the cerebral hemorrhage disease is convenient to take, short in treatment course, quick in effect, free of toxic and side effects and free of drug dependence. The traditional Chinese medicine has the effects of activating blood stasis, stopping bleeding, dredging lung and purging heat, reducing intracerebral hematoma, reducing intracranial pressure, relieving encephaledema and promoting recovery of nerve function. The raw materials of the traditional Chinese medicine can fully utilize the resources of artificial planting, the sufficiency of the raw material resources is guaranteed, the efficiency is high, and the economic benefit and the social benefit are obvious.
The foregoing is directed to preferred embodiments of the present invention, other and further embodiments of the invention may be devised without departing from the basic scope thereof, and the scope thereof is determined by the claims that follow. However, any simple modification, equivalent change and modification of the above embodiments according to the technical essence of the present invention are within the protection scope of the technical solution of the present invention.
Claims (5)
1. The traditional Chinese medicine for treating the cerebral hemorrhage disease is characterized by comprising the following raw materials in parts by weight: 30-35 parts of scorpion, 15-25 parts of uncaria, 30-35 parts of earthworm, 25-30 parts of typhonium giganteum, 5-10 parts of cassia twig, 25-30 parts of salvia miltiorrhiza, 2-4 parts of apocynum venetum, 30-35 parts of gastrodia elata, 5-6 parts of fructus cannabis, 30-35 parts of rhizoma acori graminei and 5-8 parts of additive, wherein the additive is a mixture of xylitol and citric acid;
the traditional Chinese medicine is prepared by the following steps:
1) weighing clean raw materials according to the parts by weight except a mixture of xylitol and citric acid, uniformly mixing, drying at 65-75 ℃ for 15-20 minutes, and uniformly stirring while drying; then, the raw materials are put into a crusher to be crushed into coarse materials, and the coarse materials are sieved by a sieve of 50-80 meshes;
2) uniformly mixing the raw materials crushed in the step 1), drying at 70-80 ℃ for 10-15 minutes, and uniformly stirring while drying; then putting the mixture into a fine crusher to be crushed into fine materials, sieving the fine materials by a sieve of 150-180 meshes, and uniformly mixing the fine materials;
3) then the admixture in parts by weight is mixed, and then the mixture is stirred evenly, bagged, packaged and sterilized to obtain the powder type traditional Chinese medicine for treating cerebral hemorrhage diseases.
2. The traditional Chinese medicine for treating cerebral hemorrhage disease as claimed in claim 1, wherein the traditional Chinese medicine is prepared from the following raw materials in parts by weight: 32 parts of scorpion, 20 parts of uncaria, 32 parts of earthworm, 28 parts of typhonium giganteum, 8 parts of cassia twig, 28 parts of salvia miltiorrhiza, 3 parts of dogbane, 32 parts of gastrodia elata, 5.5 parts of fructus cannabis and 32 parts of rhizoma acori graminei.
3. The traditional Chinese medicine for treating cerebral hemorrhage disease as claimed in claim 1 or 2, wherein 1 part by weight of the raw materials is 10 g.
4. The traditional Chinese medicine for treating cerebral hemorrhage disease as claimed in claim 3, wherein the weight ratio of xylitol and citric acid in the admixture is 1: 0.5.
5. The traditional Chinese medicine for treating cerebral hemorrhage disease as claimed in claim 4, wherein the weight of the bag is 20 g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410014178.1A CN103705761B (en) | 2014-01-14 | 2014-01-14 | Traditional Chinese medicine for treating cerebral hemorrhage diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410014178.1A CN103705761B (en) | 2014-01-14 | 2014-01-14 | Traditional Chinese medicine for treating cerebral hemorrhage diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103705761A CN103705761A (en) | 2014-04-09 |
| CN103705761B true CN103705761B (en) | 2014-08-27 |
Family
ID=50399348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410014178.1A Expired - Fee Related CN103705761B (en) | 2014-01-14 | 2014-01-14 | Traditional Chinese medicine for treating cerebral hemorrhage diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103705761B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104758835B (en) * | 2015-04-07 | 2015-11-04 | 陈双成 | A kind of Chinese medicine being used for the treatment of cerebral infarction disease |
-
2014
- 2014-01-14 CN CN201410014178.1A patent/CN103705761B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN103705761A (en) | 2014-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104825591A (en) | Traditional Chinese medicine preparation for treating cervical vertebra diseases and preparation method of traditional Chinese medicine preparation | |
| CN106728958A (en) | Pharmaceutical composition for treating muscles and bones arthralgia | |
| CN104206916A (en) | Functional feed for treating ichthyoxeniosis of carps and preparation method of functional feed | |
| CN103263529B (en) | Traditional Chinese medicine composition for treating bone fracture | |
| CN109432269A (en) | A kind of Chinese medicine composition and preparation method, purposes | |
| JPH07300423A (en) | Medicinal composition for preventing or curing premature ejaculation | |
| CN102772712A (en) | Traditional Chinese medicine composition for treating heat-toxicity, flourishing and blood stasis type diabetic foot | |
| CN108619473A (en) | A kind of Chinese medicine fuming-lotion for treating diabete peripheral herve pathology | |
| CN102406766A (en) | Traditional Chinese medicine composition for treating bone fracture and application thereof | |
| CN103705761B (en) | Traditional Chinese medicine for treating cerebral hemorrhage diseases | |
| CN106902257A (en) | A kind of Chinese medicine composition of facial paralysis and preparation method thereof | |
| CN102784355B (en) | First-aid drug and preparation method thereof | |
| CN103751309A (en) | Traditional Chinese medicine external preparation for treating intercostal neuralgia and preparation method thereof | |
| CN107007784A (en) | Chinese medicine composition for reversing A amyloid beta damaged nerve cells and preparation method and application | |
| CN104721631A (en) | Traditional Chinese medicine composition for promoting wound healing and preparation method of traditional Chinese medicine composition | |
| CN106729939B (en) | A kind of dressing for treating bedsore | |
| RU2326683C2 (en) | Wound healing, anti-inflammatory ointment | |
| CN103989969A (en) | Traditional Chinese medicament for treating wind-cold obstruction type cervical spondylotic radiculopathy and preparation method thereof | |
| CN109157566A (en) | A kind of gynecological gel preparation of anti-inflammation and sterilization and preparation method thereof | |
| CN108420877A (en) | It is a kind of to treat traumatic injury and swelling and pain relieving Chinese medicine preparation | |
| CN106729443A (en) | A kind of Chinese medicine composition for swelling and pain relieving and preparation method thereof | |
| CN104189313A (en) | Medicinal composition for treating crucian carp ichthyoxeniosis and preparation method thereof | |
| CN105663540A (en) | Traditional Chinese medicine composition for treating cerebral concussion sequelae | |
| CN103705703B (en) | Traditional Chinese medicine for treating cardiovascular and cerebrovascular diseases | |
| CN105125926A (en) | Medical powder for treating burns and scalds and preparation method of medical powder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140827 Termination date: 20160114 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |